Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type Colorectal Cancer in First-line Treatment: a Prospective, Observational Multi-centre Study in Spain. PERSEIDA Study
Latest Information Update: 19 Oct 2022
At a glance
- Drugs Panitumumab (Primary)
- Indications Carcinoma; Colorectal cancer
- Focus Pharmacodynamics
- Acronyms PERSEIDA
- Sponsors Amgen
Most Recent Events
- 13 Sep 2022 Results assessing sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type, presented at the 47th European Society for Medical Oncology Congress
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 17 Jun 2021 Status changed from active, no longer recruiting to completed.